| Pair Name | Levistolide A, Doxorubicin | ||
| Phytochemical Name | Levistolide A (PubChem CID: 70698035 ) | ||
| Anticancer drug Name | Doxorubicin (PubChem CID: 31703 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Drug Name | Doxorubicin |
| Adverse Reactions | Nausea, vomiting, diarrhoea. This was inferred cold nature anticancer drug. |
| Recommendations | Hot: Ligusticum chuam; Angelica sinensis; Zingiber officinale; Panax ginseng; Pogostemon cablin |
| Reference | ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899. ref_link |
| Pair Name | Levistolide A, Doxorubicin | |||
| Disease Info | [ICD-11: 2B33.2] | Chronic myeloid leukemia | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Down-regulation | Expression | ABCB1 | hsa5243 | |
| Up-regulation | Expression | CASP3 | hsa836 | |
| In Vitro Model | K562/dox | Doxorubicin-resistant blast phase chronic myelogenous leukemia | Homo sapiens (Human) | N.A. |
| Result | Levistolide A synergistically enhances doxorubicin‑induced apoptosis of k562/dox cells by decreasing MDR1 expression through the ubiquitin pathway | |||
| No. | Title | Href |
|---|---|---|
| 1 | Levistolide A synergistically enhances doxorubicin‑induced apoptosis of k562/dox cells by decreasing MDR1 expression through the ubiquitin pathway. Oncol Rep. 2019 Feb;41(2):1198-1208. doi: 10.3892/or.2018.6889. | Click |
